TABLE 7.

Top 20 highly cited ESI publications from 2011 to 2020.

No	Author (PY)	Title	TC	TCPY	Journal	Institution,Country/Region	OPC
1	Wishart, DS et al. (2018)	DrugBank 5.0: a major update to the DrugBank database for 2018	1820	606.7	Nucleic Acids Res	Univ Alberta, Canada et al.	None
2	Pushpakom, S et al. (2019)	Drug repurposing: progress, challenges and recommendations	885	442.5	Nat. Rev. Drug Discov	Univ Liverpool, England et al.	None
3	Maier, L et al. (2018)	Extensive impact of non-antibiotic drugs on human gut bacteria	639	213.0	Nature	European Mol Biol Lab, Germany et al.	Japan
4	Zhou, YD et al. (2020); Cheng, FX et al. (2020)	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2	609	609.0	Cell Discov	Cleveland Clin, United States et al.	None
5	Anighohro, A et al. (2014)	Polypharmacology: Challenges and Opportunities in Drug Discovery	492	70.3	J. Med. Chem	Univ Modena and Reggio Emilia, Italy et al.	Germany
6	Cheng, FX et al. (2012)	Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference	491	54.6	PLoS Comput. Biol	E China Univ Sci and Technol, Peoples R China	None
7	Langhans, SA (2018)	Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning	395	131.7	Front. Pharmacol	Alfred I DuPont Hosp Children, United States	None
8	Xu, M et al. (2016)	Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen	389	77.8	Nat. Med	NIH, United States et al.	China
9	Sirota, M et al. (2011); Dudley, JT et al. (2011)	Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data	327	32.7	Sci. Transl. Med	Stanford Univ, United States	None
10	Sriram, K et al. (2018)	G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?	311	103.7	Mol. Pharmacol	Univ Calif San Diego, United States	None
11	Dudley, JT et al. (2011)	Exploiting drug-disease relationships for computational drug repositioning	282	28.2	Brief. Bioinform	Arizona State Univ, United States et al.	None
12	Medina-Franco, JL et al. (2013)	Shifting from the single to the multitarget paradigm in drug discovery	285	35.6	Drug Discov. Today	Univ Nacl Autonoma Mexico, Mexico et al.	The United States
13	Peters, JU (2013)	Polypharmacology - Foe or Friend?	275	34.4	J. Med. Chem	F Hoffmann La Roche Ltd., Switzerland	None
14	Yoshida, GJ et al. (2015)	Metabolic reprogramming: the emerging concept and associated therapeutic strategies	255	42.5	J. Exp. Clin. Cancer Res	Japan Soc Promot Sci, Japan	None
15	Skrott, Z et al. (2017)	Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4	249	62.3	Nature	Palacky Univ/Czech Republic et al.	Denmark; Sweden; Switzerland; The United States; China
16	Li, J et al. (2016)	A survey of current trends in computational drug repositioning	242	48.4	Brief. Bioinform	Chinese Acad Med Sci, Peoples R China et al.	The United States
17	Stokes, JM et al. (2020)	A Deep Learning Approach to Antibiotic Discovery	235	235	Cell	MIT, United States et al.	Canada
18	Reddy, AS et al. (2013)	Polypharmacology: drug discovery for the future	228	28.5	Expert Rev. Clin. Pharmacol	Univ Texas Houston, United States	None
19	Menden, MP et al. (2013)	Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties	229	28.6	PLoS One	Wellcome Trust Genome Campus Cambridge, England et al.	The United States
20	Beck, BR et al. (2020)	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	225	225	Comp. Struct. Biotechnol. J	Deargen Inc., South Korea et al.	The United States

Notes: PY, publication year; TC, total citations; TCPY, total citations per year; and OPC, other partner countries.